Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2021-08, Vol.144 (8), p.655-658 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 658 |
|---|---|
| container_issue | 8 |
| container_start_page | 655 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 144 |
| creator | Lackey, Leila G. Garnett, Christine E. Senatore, Fred |
| description | |
| doi_str_mv | 10.1161/CIRCULATIONAHA.120.053294 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8422229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564131292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4688-8bcf27487d0028314f89cd7ca7378171eff5c1c174d432dc4076d97dd32ea573</originalsourceid><addsrcrecordid>eNpVUt1u0zAUjhCIlcErIHPHTYr_Uic3SFm30UgdQ2t2bXm205o6cWcnm3q3d-CKl-Fh9iS4ypiYb458zvdzrM9J8gnBKUIz9GVeXc2vl2VdXX4vF-UUYTiFGcEFfZVMUIZpSjNSvE4mEMIiZQTjo-RdCD_jdUZY9jY5IpRiyhiaJH_K3c7uTbcGp1qaYFwHyk7YfTAB9A5UXeN8C_qNBtcrcO6cAqJT4NQPa1Cq1nQm9F70kfb48DuAE93pxvSPD7-uTNiCMgQdQqu7HrgG1EaKtdfWeRBFwQ9vWuH3seq7iDg4R9DF3knhlRH24C28HAcerHrvthqciKAViK16cXZRrd4nbxphg_7wVI-T-vysni_S5eW3al4uU0lneZ7mN7LBjOZMQYhzgmiTF1IxKRhhOWJIN00mkUSMKkqwkhSymSqYUgRrkTFynHwdZXfDTauVjPt6YflufAJ3wvCXk85s-Nrd8ZzieIoo8PlJwLvbQYeetyZIba3otBsCx9mMIoJwgSO0GKHSuxC8bp5tEOSH-PnL-HmMn4_xR-7H__d8Zv7LOwLoCLh3ttc-bO1wrz3faGH7DY8fBBKIWIohRjDHFKaHVk7-At9Dwrc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564131292</pqid></control><display><type>article</type><title>Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lackey, Leila G. ; Garnett, Christine E. ; Senatore, Fred</creator><creatorcontrib>Lackey, Leila G. ; Garnett, Christine E. ; Senatore, Fred</creatorcontrib><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.120.053294</identifier><identifier>PMID: 34424771</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Adverse Drug Reaction Reporting Systems ; Decision Support Techniques ; Humans ; Myocardial Infarction - prevention & control ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - therapeutic use ; Primary Prevention ; Purinergic P2Y Receptor Antagonists - administration & dosage ; Purinergic P2Y Receptor Antagonists - therapeutic use ; Risk Assessment ; Stroke - prevention & control ; Ticagrelor - administration & dosage ; Ticagrelor - therapeutic use ; United States ; United States Food and Drug Administration</subject><ispartof>Circulation (New York, N.Y.), 2021-08, Vol.144 (8), p.655-658</ispartof><rights>Lippincott Williams & Wilkins</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4688-8bcf27487d0028314f89cd7ca7378171eff5c1c174d432dc4076d97dd32ea573</citedby><cites>FETCH-LOGICAL-c4688-8bcf27487d0028314f89cd7ca7378171eff5c1c174d432dc4076d97dd32ea573</cites><orcidid>0000-0002-4108-2511 ; 0000-0001-8434-2638</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3673,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34424771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lackey, Leila G.</creatorcontrib><creatorcontrib>Garnett, Christine E.</creatorcontrib><creatorcontrib>Senatore, Fred</creatorcontrib><title>Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><subject>Adverse Drug Reaction Reporting Systems</subject><subject>Decision Support Techniques</subject><subject>Humans</subject><subject>Myocardial Infarction - prevention & control</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Primary Prevention</subject><subject>Purinergic P2Y Receptor Antagonists - administration & dosage</subject><subject>Purinergic P2Y Receptor Antagonists - therapeutic use</subject><subject>Risk Assessment</subject><subject>Stroke - prevention & control</subject><subject>Ticagrelor - administration & dosage</subject><subject>Ticagrelor - therapeutic use</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUt1u0zAUjhCIlcErIHPHTYr_Uic3SFm30UgdQ2t2bXm205o6cWcnm3q3d-CKl-Fh9iS4ypiYb458zvdzrM9J8gnBKUIz9GVeXc2vl2VdXX4vF-UUYTiFGcEFfZVMUIZpSjNSvE4mEMIiZQTjo-RdCD_jdUZY9jY5IpRiyhiaJH_K3c7uTbcGp1qaYFwHyk7YfTAB9A5UXeN8C_qNBtcrcO6cAqJT4NQPa1Cq1nQm9F70kfb48DuAE93pxvSPD7-uTNiCMgQdQqu7HrgG1EaKtdfWeRBFwQ9vWuH3seq7iDg4R9DF3knhlRH24C28HAcerHrvthqciKAViK16cXZRrd4nbxphg_7wVI-T-vysni_S5eW3al4uU0lneZ7mN7LBjOZMQYhzgmiTF1IxKRhhOWJIN00mkUSMKkqwkhSymSqYUgRrkTFynHwdZXfDTauVjPt6YflufAJ3wvCXk85s-Nrd8ZzieIoo8PlJwLvbQYeetyZIba3otBsCx9mMIoJwgSO0GKHSuxC8bp5tEOSH-PnL-HmMn4_xR-7H__d8Zv7LOwLoCLh3ttc-bO1wrz3faGH7DY8fBBKIWIohRjDHFKaHVk7-At9Dwrc</recordid><startdate>20210824</startdate><enddate>20210824</enddate><creator>Lackey, Leila G.</creator><creator>Garnett, Christine E.</creator><creator>Senatore, Fred</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4108-2511</orcidid><orcidid>https://orcid.org/0000-0001-8434-2638</orcidid></search><sort><creationdate>20210824</creationdate><title>Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS</title><author>Lackey, Leila G. ; Garnett, Christine E. ; Senatore, Fred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4688-8bcf27487d0028314f89cd7ca7378171eff5c1c174d432dc4076d97dd32ea573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse Drug Reaction Reporting Systems</topic><topic>Decision Support Techniques</topic><topic>Humans</topic><topic>Myocardial Infarction - prevention & control</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Primary Prevention</topic><topic>Purinergic P2Y Receptor Antagonists - administration & dosage</topic><topic>Purinergic P2Y Receptor Antagonists - therapeutic use</topic><topic>Risk Assessment</topic><topic>Stroke - prevention & control</topic><topic>Ticagrelor - administration & dosage</topic><topic>Ticagrelor - therapeutic use</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lackey, Leila G.</creatorcontrib><creatorcontrib>Garnett, Christine E.</creatorcontrib><creatorcontrib>Senatore, Fred</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lackey, Leila G.</au><au>Garnett, Christine E.</au><au>Senatore, Fred</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2021-08-24</date><risdate>2021</risdate><volume>144</volume><issue>8</issue><spage>655</spage><epage>658</epage><pages>655-658</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>34424771</pmid><doi>10.1161/CIRCULATIONAHA.120.053294</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-4108-2511</orcidid><orcidid>https://orcid.org/0000-0001-8434-2638</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2021-08, Vol.144 (8), p.655-658 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8422229 |
| source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adverse Drug Reaction Reporting Systems Decision Support Techniques Humans Myocardial Infarction - prevention & control Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - therapeutic use Primary Prevention Purinergic P2Y Receptor Antagonists - administration & dosage Purinergic P2Y Receptor Antagonists - therapeutic use Risk Assessment Stroke - prevention & control Ticagrelor - administration & dosage Ticagrelor - therapeutic use United States United States Food and Drug Administration |
| title | Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T12%3A01%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Applying%20Decision%20Analysis%20to%20Inform%20the%20US%20Food%20and%20Drug%20Administration%E2%80%99s%20Benefit%E2%80%93Risk%20Assessment%20of%20Ticagrelor%20for%20Primary%20Prevention%20of%20Myocardial%20Infarction%20or%20Stroke%20Based%20on%20THEMIS&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Lackey,%20Leila%20G.&rft.date=2021-08-24&rft.volume=144&rft.issue=8&rft.spage=655&rft.epage=658&rft.pages=655-658&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/CIRCULATIONAHA.120.053294&rft_dat=%3Cproquest_pubme%3E2564131292%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564131292&rft_id=info:pmid/34424771&rfr_iscdi=true |